Journal profile · MEDICINE, GENERAL & INTERNAL
BioMedicine-Taiwan
ISSN 2211-8020 · eISSN 2211-8039 · China Medical University · Taiwan, Province of China
BioMedicine-Taiwan: CAS Zone 4 · Medicine (2025 upgraded edition); diamond open access (no APC); no APC; median 34 days to acceptance (33 articles, last 24 months); 27 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
BioMedicine-Taiwan is published by China Medical University and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Drug-Induced Hepatotoxicity and Protection, Spine and Intervertebral Disc Pathology and Peroxisome Proliferator-Activated Receptors, together about 17.7% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
BioMedicine, a peer-reviewed, open access quarterly journal, publishes high-quality scientific research in the fields of precision medicine with the goal of promoting and disseminating medical knowledge to improve global health. Articles of interest on clinical, laboratory, and social research in precision medicine and articles regarding health issues and herbal medicine are eligible for consideration. Reviews, originals, case reports, short communications, and letters to the editor are also accepted.
From the journal's Aims & Scope
Research area (LetPub): MEDICINE, GENERAL & INTERNAL
Editor-in-chief Ferid MuradPublisher website
Editorial board by country: 1 in mainland China (about 4%); most named Taiwan, China 13, United States 5, Canada 2, Mainland China 1, United Kingdom 1 (27 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Drug-Induced Hepatotoxicity and ProtectionPharmacology, Toxicology and Pharmaceutics6.8%
- Spine and Intervertebral Disc PathologyMedicine5.6%
- Peroxisome Proliferator-Activated ReceptorsBiochemistry, Genetics and Molecular Biology5.2%
- Cancer, Lipids, and MetabolismBiochemistry, Genetics and Molecular Biology5.2%
- Sleep and related disordersPsychology4.8%
- Liver Disease Diagnosis and TreatmentMedicine4.8%
- Traditional Chinese Medicine AnalysisMedicine4.8%
- Adipokines, Inflammation, and Metabolic DiseasesMedicine4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, General & Internal | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Medicine, General & Internal | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 4.2LetPub ·
- SJR 2026-06
- 0.59LetPub ·
- SNIP 2026-06
- 0.77LetPub ·
- h-index
- 44OpenAlex ·
- i10-index
- 226OpenAlex ·
- 2-year mean citedness
- 1.04OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 98.59%LetPub ·
Volume
- Articles per year
- 26LetPub ·
Articles by year OpenAlex count · 580 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 26 | 26 | 1 |
| 2025 | 27 | 27 | 52 |
| 2024 | 185 | 185 | 194 |
| 2023 | 27 | 27 | 248 |
| 2022 | 28 | 28 | 264 |
| 2021 | 33 | 33 | 531 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
34 daysMedian, submission to acceptance · P25–P75 20 days – 46 days
- Acceptance to online
- median 216 days (33 articles)
- Submission to online
- median 263 days
- Sample
- 33 articles with submission and acceptance dates (49 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 24 weeksLetPub ·
- Submission to publication (journal-reported)
- about 24 weeksDOAJ ·
- Peer review
- Unspecified peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Diamond open access (no APC)DOAJ
Every article is open access and authors pay no article processing charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | No APC | No | CC BY | |
| LetPub | No APC | No | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare9 items from the author guidelines
- Abstract
- ≤ 300 words
- Keywords
- 3–5
- Manuscript length
- ≤ 5,500 words
- Reference style
- Numbered, in order of citation
- Templates
- Word
- First submission
- Free format: the journal's layout is not required
- Suggested reviewers
- Optional
- Highlights
- Optional
- Graphical abstract
- Optional
Policy excerpts from the journal's websiteConflicts of interest, Peer review
- Conflicts of interest 8.4. Acknowledgments and Conflicts of Interest Statement
General acknowledgments for consultations, statistical analysis, etc., should be listed concisely at the end of the text, including the names of the individuals who were directly involved. Consent should be obtained from those individuals before their names are listed in this section. All financial and material support for the research and work from internal or external agencies, including commerc…
Source ↗Publisher website ·- Peer review 10. The Editorial and Peer Review Process
As a general rule, the receipt of a manuscript will be acknowledged within 1 week of submission, and authors will be provided with a manuscript reference number for future correspondence. If such an acknowledgment is not received in a reasonable period of time, the author should contact the Editorial Office. Submissions are reviewed by the Editorial Office to ensure that it contains all parts. The…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- China Medical University
- Country or region
- Taiwan, Province of China
- Language
- English
- ISSN
- 2211-8020
- Electronic ISSN
- 2211-8039
- Latest issue on the website
- Volume 16, Issue 3 (2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about BioMedicine-Taiwan
What CAS zone is BioMedicine-Taiwan in?
In the 2025 upgraded edition of the CAS Journal Ranking, BioMedicine-Taiwan is in Zone 4 of Medicine, and in Zone 4 of the minor category Medicine, General & Internal. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
How long does peer review take at BioMedicine-Taiwan?
Based on the dates recorded on 33 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 34 days (interquartile range 20–46 days); authors report an average review time of about 24 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of BioMedicine-Taiwan?
According to the journal's author guidelines: Abstract: ≤ 300 words; Keywords: 3–5; Manuscript length: ≤ 5,500 words; Reference style: Numbered, in order of citation; Templates: Word; First submission: Free format: the journal's layout is not required; Suggested reviewers: Optional; Highlights: Optional; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of BioMedicine-Taiwan based?
Of the 27 board members whose country the journal's board page names, 1 (about 4%) are in mainland China; the countries named most often are Taiwan, China (13), United States (5) and Canada (2). Counted from the institutions listed on the board page; for reference only.
Which databases index BioMedicine-Taiwan?
According to LetPub and DOAJ records, BioMedicine-Taiwan is indexed in ESCI, Scopus and DOAJ.
Is BioMedicine-Taiwan open access, and what is the APC?
BioMedicine-Taiwan is a diamond open-access journal (no APC). It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .